About this trial
Patients with early pancreatic cancer often have symptoms that could also be caused by many common benign conditions, or no symptoms at all. Jaundice, weight loss and pain are 'red flag' symptoms of pancreatic cancer that are linked to incurable disease. At the moment only patients with 'red flag' symptoms are urgently referred for diagnostic testing to find out if they have the cancer. As a result, late diagnosis is a common feature of pancreatic cancer. This leads to limited treatment options being available to patients by the time they are diagnosed, and ultimately results in poor survival rates.
There is a clear need to improve earlier detection of pancreatic cancer so that patients with pancreatic cancer can be identified earlier and faster, enabling them to start treatment more quickly.
The study team is developing a non-invasive breath test that detects small molecules called volatile organic compounds (VOCs) that may be altered by pancreatic cancers. For patients with non-specific symptoms, this test would help general practitioners (GPs) to identify those patients that may indeed have an underlying pancreatic cancer, who would benefit from referral for specialised pancreatic cancer tests.
Eligibility criteria
Qualifiers
Males and females
Adult patients ≥ 18 years old
VAPOR 1: patients with either a) Histologically confirmed PDAC*; b) New-onset diabetes mellitus or chronic pancreatitis; or c) Non-specific gastrointestinal symptoms, but a radiologically-normal pancreas
VAPOR Bioresource: patients undergoing pancreatic resection for a) Histologically confirmed PDAC*; or b) Benign pancreatic disorders e.g. intraductal papillary mucinous neoplasms, pancreatic mucinous cystic neoplasms, chronic pancreatitis
Disqualifiers
Patients who have already received chemotherapy, radiotherapy or surgery for their PDAC
History of another cancer within the previous five years
Previous upper gastrointestinal surgery
Patients who are unable to provide a breath sample
Trial design
Treatments tested in this trial
- Breath test
- Collection of matched samples of breath, biofluids and pancreatic tissue
Treatment groups
Sponsors and collaborators
Imperial College London
Lead sponsor
Pancreatic Cancer UK
Collaborator
Imperial College Healthcare NHS Trust
Collaborator
Royal Free Hospital NHS Foundation Trust
Collaborator
Liverpool University Hospitals NHS Foundation Trust
Collaborator
The Leeds Teaching Hospitals NHS Trust
Collaborator
Sheffield Teaching Hospitals NHS Foundation Trust
Collaborator
University Hospital Southampton NHS Foundation Trust
Collaborator
Royal Surrey County Hospital NHS Foundation Trust
Collaborator
University Hospital Birmingham NHS Foundation Trust
Collaborator
Manchester University NHS Foundation Trust
Collaborator
Newcastle-upon-Tyne Hospitals NHS Trust
Collaborator
Swansea Bay University Health Board
Collaborator
Dorset County Hospital NHS Foundation Trust
Collaborator
North Tees and Hartlepool NHS Foundation Trust
Collaborator
University Hospital Plymouth NHS Trust
Collaborator
Barts & The London NHS Trust
Collaborator
Milton Keynes University Hospital NHS Foundation Trust
Collaborator
Buckinghamshire Healthcare NHS Trust
Collaborator
Southern Health
Collaborator